Table 5. Patient and treatment features according to TIL (n=79).
| Variables | TIL ≤10%, n (%) | TIL >10%, n (%) | P value |
|---|---|---|---|
| Quadrant | 0.445 | ||
| Outer | 39 (61.9) | 9 (56.3) | |
| Upper-inner | 4 (6.4) | 0 (0.00) | |
| Lower-inner/central | 20 (31.7) | 7 (43.7) | |
| Histological grade | 0.876 | ||
| I | 10 (15.8) | 2 (12.5) | |
| II | 44 (69.8) | 11 (68.7) | |
| III | 9 (14.4) | 3 (18.8) | |
| PCR | 0.565 | ||
| Yes | 7 (11.1) | 1 (6.2) | |
| No | 56 (88.9) | 15 (93.8) | |
| Type of surgery | 0.965 | ||
| BCS | 24 (38.1) | 6 (37.5) | |
| MRM | 39 (61.9) | 10 (62.5) | |
| Clinical stage | 0.573 | ||
| II | 44 (69.8) | 10 (62.5) | |
| III | 19 (30.2) | 6 (37.5) | |
| IMN-RT | 0.725 | ||
| Yes | 6 (9.5) | 2 (12.5) | |
| No | 57 (90.5) | 14 (87.5) | |
| Luminal subtype | 0.955 | ||
| Luminal A | 32 (50.8) | 8 (50.0) | |
| Luminal B | 31 (49.2) | 8 (50.0) | |
| Pretreatment LMR | 0.386 | ||
| >5.2 | 40 (63.4) | 12 (75.0) | |
| ≤5.2 | 23 (36.6) | 4 (25.0) | |
| KI67 | 0.696 | ||
| ≤20% | 31 (50.0) | 7 (43.8) | |
| >20% | 32 (50.0) | 9 (56.2) | |
| Margin | 0.412 | ||
| Negative | 56 (88.9) | 13 (81.2) | |
| Positive | 7 (11.1) | 3 (18.8) | |
| ypN0 | 0.488 | ||
| Yes | 18 (28.6) | 6 (37.5) | |
| No | 45 (71.4) | 10 (62.5) | |
| PR | 0.218 | ||
| Negative | 12 (19.0) | 1 (6.2) | |
| Positive | 51 (81.0) | 15 (93.8) | |
| RT | 0.198 | ||
| Yes | 32 (50.8) | 11 (68.8) | |
| No | 31 (49.2) | 5 (31.2) | |
| Pathological stage | 0.272 | ||
| 0–II | 47 (74.6) | 14 (87.5) | |
| III | 16 (25.4) | 2 (12.5) | |
| Standard endocrine therapy | 0.237 | ||
| Yes | 47 (75.0) | 10 (62.5) | |
| No | 14 (25.0) | 6 (37.5) |
BCS, breast-conserving surgery; IMN-RT, internal mammary node radiotherapy; LMR, lymphocyte-to-monocyte ratio; MRM, modified radical mastectomy, pCR, pathological complete response; PR, progesterone receptor; TIL, tumor-infiltrating lymphocytes; ypN0, N0 after neoadjuvant chemotherapy.